1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/news/Leukemia-might-be-linked-to-CYP2D6-CYP1A1-CYP2E1-GSTT1-and-GSTM1-genes-591.html

Leukemia might be linked to CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes

06-12-2006

Leukemia might be linked to CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes.

According to recent research from Turkey, "Acute leukemias (ALs) are heterogeneous diseases. Functional polymorphisms in the genes encoding detoxification enzymes cause inter-individual differences, which contribute to leukemia susceptibility."

"The CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 polymorphisms in ALL (n=156) and AML (n=94) patients and 140 healthy controls were genotyped by PCR and/or PCR-RFLP using blood or bone marrow samples," explained M. Aydinsayitoglu and colleagues, Institute for Experimental Medical Research DETAE. "No association was observed between the GSTT1 gene deletion and patients (OR=.8, 95% CI=.4-1.7 for AMLs and OR=.9, 95% CI=.5-1.6 for ALLs). Patients with ALL and AML had a higher prevalence of the GSTM1 deletions compared to controls but only the difference among adult AML patients (OR=2.1, 95% CI=1.0-4.2) was statistically significant.

"The CYP2D63 variant allele frequency was lower in the overall acute leukemia patients (.6%) compared to controls (p=.03). CYP2D61/3 genotype frequency also showed a protective association in AML patients (OR=.09, 95% CI=.01-1.7; p=.04). We also found a risk association for CYP2E15 in ALL and AML (OR=3.6, 95% CI=1.4-9.4 and OR=3.9, 95% CI=1.4-10.5, respectively). No association was found for the studied CYP2D64, CYP1A1 2A, and GSTT1 'null' variants and the risk of acute leukemia (ALL or AML)."

The researchers concluded, "This case-control study suggests a contribution of CYP2E1, CYP2D6, and GSTM1 'null' variants to the development of acute leukemias."

Aydinsayitoglu and colleagues published their study in American Journal of Hematology (Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias. Am J Hematol, 2006;81(3):162-170).

For additional information, contact U. Ozbek, Institute for Experimental Medical Research DETAE, Dept. Genetics, Vakif Gureba Cad, TR-34093 Istanbul, Turkey.

Publisher contact information for the American Journal of Hematology is: Wiley-Liss, Division John Wiley & Sons Inc., 111 River St., Hoboken, NJ 07030, USA.

Keywords: Istanbul, Turkey, Acute Leukemia, Bone Marrow, CYP1A1, CYP2D6, CYP2E1, Diagnosis, Diagnostics, Epidemiology, GSTM1, GSTT1, Genotyping, Hematology, Cancer Development, Oncogenes, Cancer Risk.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.